A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors
Clinical trial NCT02494596 · COMPLETED
Trial details
- NCT number
- NCT02494596
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2004-01-01
- Primary completion
- 2005-09-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.